Contact Us
Drug Search Results
More Filters [+]

Choline alfoscerate

Alternative Names: choline alfoscerate, choline alphoscerate
Latest Update: 2024-03-26
Latest Update Note: PubMed Publication

Product Description

Choline alfoscerate is a member of the class of phosphocholines that is the choline ester of sn-glycero-3-phosphate. It is one of the major osmolyte in the renal medullary cells (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Choline-Alfoscerate)

Mechanisms of Action: GM2 Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Greece | Italy | Korea | Pakistan | Philippines | Poland | Russia | Ukraine | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: AZIENDA OSPEDALIERA CARDARELLI
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Choline alfoscerate

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Cognitive Dysfunction|Alzheimer Disease|Stroke|Dementia

Phase 3: Type 2 Diabetes

Phase 2: Alzheimer Disease|Cognitive Dysfunction

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
COALA

P4

Recruiting

Alzheimer Disease

2025-06-30

ESCALADE

P4

Unknown status

Cognitive Dysfunction

2024-11-30

INFINITE-V (B78_03VCI2004)

P4

Unknown status

Cognitive Dysfunction

2024-11-01

CHOLDEPS

N/A

Unknown status

Depressive Disorder, Major

2023-03-01

Recent News Events

Date

Type

Title

03/26/2024

PubMed

 Pharmacological enhancement of cholinergic neurotransmission alleviates neuroinflammation and improves functional outcomes in a triple transgenic mouse model of Alzheimer's disease.

03/07/2024

PubMed

 Glycerophospholipids in Red Blood Cells Are Associated with Aerobic Performance in Young Swimmers.

01/01/2024

PubMed

 [Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study].

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions